The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia

Molecular Psychiatry

Volumn 7, Issue 3, 2002, Pages 247-253

  Pani, L ^a   Gessa, G L ^a  

^a CNR   (Italy)

Author keywords

Affective disorders; Antidepressant; Depression; Dopamine; Limbic system

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; BENZAMIDE DERIVATIVE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SULPIRIDE;

AFFECTIVE NEUROSIS; ARTICLE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSTHYMIA; HUMAN; LIMBIC SYSTEM; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANTIDEPRESSIVE AGENTS; BENZAMIDES; DYSTHYMIC DISORDER; HUMANS; RECEPTORS, DOPAMINE D1; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP; SULPIRIDE;

EID: 0036219144     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001040     Document Type: Article

References (112)

1. A history of antipsychotic drug development
2. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
3. Prolactin and antipsychotic medications: Mechanism of action
4. Weight gain from atypical neuroleptics - An underreported adverse effect?
5. Antipsychotic-induced weight gain: A comprehensive research synthesis
6. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
7. The development of dopamine D2-receptor selective antagonists
8. Depression in schizophrenia: Perspective in the era of 'atypical' antipsychotic agents
9. Dopamine and Mental Depression
10. Therapy of various forms of senile depressions with sulpirid (Dogmatil)
11. Sulpiride vs amitriptyline in the treatment of depression
12. Sulpiride and psychic decompensation
13. Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and locomotor activity
14. (-)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanesthetized rats
15. Possible mechanism of antidepressant effect of L-sulpiride
16. Therapeutic effects and side effects in patients with major depression treated with sulpiride once a day
17. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: A double-blind, comparative study
18. Effect of sulpiride on endovenous depression
19. The evaluation of the anti-autistic activity of sulpiride
20. Efficacy of low doses of atypical neuroleptics (benzamides) in defect states
21. Treatment of negative symptoms in schizophrenia with neuroleptics
22. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
23. The effect of sulpiride on the central nervous system
24. Does olanzapine have antidepressant properties? A retrospective preliminary study
25. Neuroleptics as antidepressants
26. The use of antipsychotic drugs in the treatment of depression
27. Thirty years of dopamine research
28. Role of catecholamine transmitters in reward systems: Implications for the neurobiology of affect
29. The brain and reward
30. Dopamine functions in appetitive and defensive behaviours
31. Dopaminergic correlates of sensory-specific satiety in the medial prefrontal cortex and nucleus accumbens of the rat
32. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?
33. Differential influence of associative and nonassociative learning mechanisms on the responsiveness of prefrontal and accumbal dopamine transmission to food stimuli in rats fed ad libitum
34. Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: Implications for the psychobiology of depression
35. The role of dopamine in the mechanism of action of antidepressant drugs
36. Antidepressants: Past, present and future
37. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain
38. Catecholamines in the brain as mediators of amphetamine psychosis
39. Striatal D2-dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography
40. Presynaptic dopaminergic function in the striatum of schizophrenic patients
41. Increased synthesis of dopamine in prefrontal cortex and striatum in drug-naive schizophrenic patients studied by use of C11-labelled l-DOPA and positron emission tomography (PET)
42. Imaging dopamine dysregulation in schizophrenia: Implication for treatment
43. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
44. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
45. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
46. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia
47. Dopamine in schizophrenia: A review and reconceptualization
48. Dopaminergic mechanisms in the pathogenesis of schizophrenia
49. The current status of the dopamine hypothesis of schizophrenia
50. The dopamine theory revisited
51. The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia
52. Novel pharmacological approaches to the treatment of schizophrenia
53. Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: An in vivo microdialysis study
54. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects
55. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
56. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
57. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment
58. Pharmacological actions of the atypical antipsychotic drug clozapine: A review
59. Clinical trials of benzamides in psychiatry
60. Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature
61. Sulpiride: An antipsychotic with selective dopaminergic antagonist properties
62. Amisulpride versus imipramine and placebo in dysthymia and major depression
63. Amisulpride versus amineptine and placebo for the treatment of dysthymia
64. New neuroleptics and experimental antipsychotics in schizophrenia
65. Selective increase of brain dopamine synthesis by sulpiride
66. Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity
67. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients
68. Profil pharmacologique et biochimique de l'amisulpride
69. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors
70. Selective dopamine D2 receptor antagonists with an atypical neuroleptic profile
71. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity
72. An open study of remoxipride, a benzamide derivative, in schizophrenia
73. Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity
74. An open multicentre study of the treatment of florid schizophrenia with remoxipride
75. Animal models of depressions: Validity and application
76. Antidepressant-like activity of amisulpride in two animal models of depression
77. Effects of acute or chronic administration of substituted benzamides in experimental models of depression in rats
78. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
79. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia
80. (+)-UH 232 and (+)-UH 242: Novel stereoselective DA receptor antagonists with preferential action on autoreceptors
81. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships
82. Role of dopamine mechanisms in affective disorders
83. Dopamine, the prefrontal cortex and schizophrenia
84. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene
85. Neurobiology of addiction
86. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa
87. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals
88. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey
89. D1- versus D2-receptor modulation of visuospatial working memory in humans
90. D1 receptors in prefrontal cells and circuits
91. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex
92. An astroglia-linked dopamine D2-receptor action in prefrontal cortex
93. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure
94. Structure and function of dopamine receptors
95. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia
96. Amisulpride: From animal pharmacology to therapeutic action
97. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
98. Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefronal cortex
99. Distribution of dopaminergic receptors in the primate cerebral cortex: Quantitative autoradiographic analysis using 3H raclopride, 3H spiperone and 3H SCH23390
100. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
101. The effect of aging on the D1 dopamine receptors in human frontal cortex
102. Age-related changes in human D1 dopamine receptors measured by positron emission tomography
103. Working-memory mediation of adult age differences in integrative reasoning
104. Profound cognitive impairments in non-human primates exposed to amphetamine
105. The cerebral cortex: A case for a common site of action of antipsychotics
106. Delineating psychopathologic clusters within dysthymia: A study of 512 out-patients without major depression
107. Evidence for a biochemical lesion in depression
108. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: Evidence in support of the catecholamine hypothesis of mood disorders
109. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: Evidence for identical binding sites